RI (at the 12th month) was reduced by more than 80% compared to the sixth month. More than 80% of patients who received FTY720 for up to 12 months were free from lesions showing active inflammation on MRI at the 12th month irrespective of their FTY720 treatment dose (1.25 mg or 5 mg).

FTY720 appeared to be well tolerated, with 91% of patients who entered the extension phase completing the 12th month on the study drug. There were no unexpected safety findings during the extension as compared to the six-month placebo-controlled phase. The most frequently reported adverse events in patients treated up to twelve months were non-serious infections (colds, influenza), headache, diarrhoea and nausea.

About FTY720
Oral FTY720 has a novel mode of action different from all available therapies. It reversibly sequesters lymphocytes away from blood and susceptible target organs such as the central nervous system (CNS), thereby reducing neuroinflammation in MS. FTY720 has been developed by Novartis Pharma and licensed from Mitsubishi Pharma Corporation.

About Multiple Sclerosis
MS is the most common inflammatory and neurodegenerative disorder of the central nervous system, including the brain, spinal cord and optic nerves. MS typically presents itself in relapsing forms. The relapsing-remitting (RRMS) course is the most common form of the disease. Patients suffer acute self-limiting attacks (relapses) of neurological dysfunction followed by complete or incomplete remission in function. Over time, transmission of electrical nerve impulses is disrupted, nerve cells are destroyed, and patients experience symptoms ranging from fatigue, tingling, numbness and blurred vision to poor muscle control with partial or complete paralysis, speech or mental impairment. About 50% of patients advance to the secondary progressive (SPMS) course within 10 years.

(Date:6/4/2020)... ... June 04, 2020 , ... Promises Behavioral ... has announced the addition of the Illness Management and Recovery program to its ... curriculum at each facility to provide programming that covers the needs for both ...

(Date:6/2/2020)... ... , ... Join Nagy Habib, Professor of Surgery, Imperial College ... in a live webinar on Monday, June 8, 2020 at ... be immensely informative in the context of clinical trials. Multiplex immunohistochemistry is the ...

(Date:5/30/2020)... ... ... Worldwide Business with kathy ireland® will be LIVE streaming this week’s episode ... at 8:00pm ET / PT – two chances to watch each night! This episode’s exclusive ... Diagnostic Solutions Laboratory . , As leaders in their industries, these three ...

(Date:5/30/2020)... ... 30, 2020 , ... HashCash Consultants is working with healthcare ... needs of a COVID-riddled world, while shaping a robust healthcare infrastructure fit for ... compliances and augment the caregiving standards through the establishment of an agile, collaborative, ...

(Date:6/3/2020)... ... June 03, 2020 , ... The Conference Forum announced the launch ... to take place on September 21st, 2020. This annual conference challenges biopharma R&D on ... for patients and physicians to participate in clinical research. , “This event comes at ...

(Date:6/3/2020)... ... 03, 2020 , ... Ridgecrest Healthcare, a skilled nursing ... CDP, ALFM-BC, as its new Executive Directory and Administrator. Villafranca assumes all the ... his career in healthcare in 1994 and has held various positions in senior ...

(Date:6/3/2020)... ... June 03, 2020 , ... GrandPad , creator ... of connected device capabilities to its mobile device and telehealth platform to support ... a time when an increasing number of home health agencies and other healthcare ...